Breaking News

Abcam Licenses Pfizer Research Compounds

June 12, 2013

Will be used as preclinical research tools

Abcam’s Biochemicals division has entered into a license agreement with Pfizer to supply a range of authentic Pfizer compounds for use as preclinical research tools, along with Abcam Biochemicals range of more than 2000 bioactive small molecules. The agreement includes Pfizer compounds atorvastatin, doxorubicin, nifedipine and bosutinib. Abcam Biochemicals range will support preclinical research in a variety of fields such as neuroscience, cardiovascular disease, cancer and antibiotic resistance.
 
Steve Roome, general manager of Abcam Biochemicals, said, “We are delighted to have signed the license agreement, and to provide authentic Pfizer compounds to our customers. The compounds are an ideal complement to our current range of exceptional quality small molecules.”
blog comments powered by Disqus
  • Setting Health-Based Exposure Limits to Support Pharmaceutical Development and Manufacturing

    Setting Health-Based Exposure Limits to Support Pharmaceutical Development and Manufacturing

    B.D. Naumann, P.J. Nigro, U. Bruen, L. Parola, D. Cragin and A. Schatz, Merck & Co., Inc. and Ashland, Inc.||May 5, 2016
    Health-based exposure limits are needed to support risk assessments

  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.